Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis.
نویسندگان
چکیده
منابع مشابه
No Association between Gadolinium-Based Contrast Agents and Development of Nephrogenic Systemic Fibrosis: a Case Study
Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is an emerging systemic fibrosing disorder that develops in the setting of renal insufficiency. Nephrogenic fibrosing dermopathy (NFD) is a fibrosing condition of the skin which shows an increased number of dendritic cells, fibroblasts and thickened collagen fibers resembling scleromyxedema. It is charact...
متن کاملImatinib in the treatment of nephrogenic systemic fibrosis.
Nephrogenic systemic fibrosis is a disabling progressive condition that is being reported with increased frequency in patients with kidney disease. Treatment is extremely limited and largely supportive. We report a case of severe nephrogenic systemic fibrosis in a dialysis patient exposed to multiple doses of gadolinium who improved clinically and histologically with treatment with imatinib.
متن کاملEvaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...
متن کاملRenal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature.
Nephrogenic systemic fibrosis (NSF) is a rare fibrosing disorder described among patients with renal disease. Currently, no standard therapy exists, although therapeutic modalities have included plasmapheresis, extracorporeal photopheresis, sodium thiosulphate, imatinib and renal transplantation. We describe a patient with NSF who was physically debilitated and underwent renal transplantation. ...
متن کاملImatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
The purpose of this study was to determine dose-limiting toxicities and pharmacokinetics of imatinib in children with refractory or recurrent Philadelphia chromosome-positive (Ph(+)) leukemias. Oral imatinib was administered daily at dose levels ranging from 260 to 570 mg/m(2). Plasma pharmacokinetic studies were performed on days 1 and 8 of course 1. There were 31 children who received 479 cou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Acta dermato-venereologica
دوره 91 4 شماره
صفحات -
تاریخ انتشار 2011